Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2026-03-02 Sale | 2026-03-03 7:08 pm | Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer | 10,539 | $22.8 | $240,289 | 89,515 (Direct) | View |
| 2025-03-03 Sale | 2025-03-04 8:06 pm | Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer | 15,103 | $42.1 | $635,836 | 118,101 (Direct) | View |
| 2024-03-01 Sale | 2024-03-05 8:08 pm | Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer | 4,768 | $53.76 | $256,328 | 101,363 (Direct) | View |
| 2023-09-05 Sale | 2023-09-06 5:51 pm | Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer | 6,000 | $37.96 | $227,760 | 51,281 (Direct) | View |
| 2023-06-19 Sale | 2023-06-21 6:17 pm | Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer | 305 | $48.2 | $14,701 | 57,281 (Direct) | View |
| 2023-03-01 Sale | 2023-03-03 7:51 pm | Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer | 3,664 | $45.25 | $165,796 | 96,744 (Direct) | View |
| 2022-06-19 Sale | 2022-06-22 7:27 pm | Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer | 295 | $54.78 | $16,160 | 36,160 (Direct) | View |
| 2022-03-01 Sale | 2022-03-03 6:11 pm | Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer | 2,713 | $66.62 | $180,740 | 61,217 (Direct) | View |
| 2021-10-14 Sale | 2021-10-18 6:58 pm | Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer | 303 | $81.14 | $24,585 | 25,030 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2026-04-16 Option Award | 2026-04-20 5:13 pm | N/A 2036-04-16 | Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer | 78,855 | $0 | 168,370 (Direct) | View |
| 2026-03-01 Option Award | 2026-03-03 7:08 pm | N/A N/A | Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer | 11,643 | $0 | 89,515 (Direct) | View |
| 2025-11-19 Option Award | 2025-11-21 5:02 pm | N/A 2035-11-19 | Rezolute Inc. | RZLT | Harris Erik Director | 33,000 | $0 | 33,000 (Direct) | View |
| 2025-03-25 Option Award | 2025-03-26 7:37 pm | N/A 2035-03-25 | Rezolute Inc. | RZLT | Harris Erik Director | 60,000 | $0 | 60,000 (Direct) | View |
| 2025-03-01 Option Award | 2025-03-04 8:06 pm | N/A 2035-03-01 | Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer | 65,502 | $0 | 118,101 (Direct) | View |
| 2024-10-03 Option Award | 2024-10-07 4:37 pm | N/A 2034-10-02 | Inozyme Pharma Inc. | INZY | Harris Erik Director | 56,000 | $0 | 56,000 (Direct) | View |
| 2024-05-31 Option Award | 2024-06-04 6:27 pm | N/A 2034-05-31 | Denali Therapeutics Inc. | DNLI | Harris Erik Director | 23,868 | $0 | 34,953 (Direct) | View |
| 2024-03-01 Option Award | 2024-03-05 8:08 pm | N/A 2034-03-01 | Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer | 54,557 | $0 | 101,363 (Direct) | View |
| 2023-06-01 Option Award | 2023-06-05 6:02 pm | N/A 2033-06-01 | Denali Therapeutics Inc. | DNLI | Harris Erik Director | 16,865 | $0 | 23,734 (Direct) | View |
| 2023-03-01 Option Award | 2023-03-03 7:51 pm | N/A 2033-03-01 | Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer | 64,063 | $0 | 96,744 (Direct) | View |
| 2022-03-01 Option Award | 2022-03-03 6:11 pm | N/A 2032-03-01 | Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer | 38,900 | $0 | 61,217 (Direct) | View |
| 2022-02-03 Option Award | 2022-02-07 6:54 pm | N/A 2032-02-03 | Denali Therapeutics Inc. | DNLI | Harris Erik Director | 27,476 | $0 | 27,476 (Direct) | View |